GTF3C6 is a general transcription factor IIIC subunit that functions as an integral component of the TFIIIC2 subcomplex, directly binding tRNA and virus-associated RNA promoters to facilitate RNA polymerase III-mediated transcription [UniProt]. Recent evidence reveals critical roles in cancer biology. GTF3C6 is highly expressed in hepatocellular carcinoma tissues and represents one of 15 gene signatures significantly associated with poor overall survival prognosis in HCC patients 1. In lung adenocarcinoma, GTF3C6 was identified as part of a 7-gene tyrosine-related risk score model with reliable diagnostic significance for predicting LUAD patient prognosis and immunotherapy response 2. Most importantly, GTF3C6 expression is driven by KRAS mutation through the PI3K pathway in LUAD, where it promotes anchorage-independent proliferation, migration, and invasion via FAK pathway activation 3. GTF3C6 knockdown reverses the malignant phenotype of KRAS-mutant LUAD cells and suppresses tumor organoid formation and in vivo growth 3. These findings establish GTF3C6 as a KRAS-downstream oncogenic driver in LUAD with potential as both a prognostic biomarker and therapeutic target.